CA1096307A - Pharmaceutical preparations - Google Patents
Pharmaceutical preparationsInfo
- Publication number
- CA1096307A CA1096307A CA220,535A CA220535A CA1096307A CA 1096307 A CA1096307 A CA 1096307A CA 220535 A CA220535 A CA 220535A CA 1096307 A CA1096307 A CA 1096307A
- Authority
- CA
- Canada
- Prior art keywords
- digoxin
- preparation
- solution
- amount
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 14
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims abstract description 165
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims abstract description 164
- 229960005156 digoxin Drugs 0.000 claims abstract description 164
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims abstract description 164
- 239000002775 capsule Substances 0.000 claims abstract description 74
- 238000002360 preparation method Methods 0.000 claims abstract description 40
- 238000000034 method Methods 0.000 claims abstract description 16
- 241000124008 Mammalia Species 0.000 claims abstract description 9
- 238000003466 welding Methods 0.000 claims abstract description 4
- 239000007916 tablet composition Substances 0.000 claims abstract description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 84
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 58
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 239000002904 solvent Substances 0.000 claims description 27
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 20
- 239000007903 gelatin capsule Substances 0.000 claims description 17
- 229920001223 polyethylene glycol Polymers 0.000 claims description 14
- 239000002202 Polyethylene glycol Substances 0.000 claims description 12
- 239000011877 solvent mixture Substances 0.000 claims description 11
- 235000011187 glycerol Nutrition 0.000 claims description 10
- 108010010803 Gelatin Proteins 0.000 claims description 9
- 239000008273 gelatin Substances 0.000 claims description 9
- 229920000159 gelatin Polymers 0.000 claims description 9
- 235000019322 gelatine Nutrition 0.000 claims description 9
- 235000011852 gelatine desserts Nutrition 0.000 claims description 9
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- 210000002438 upper gastrointestinal tract Anatomy 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000004090 dissolution Methods 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 238000004040 coloring Methods 0.000 claims description 2
- 239000004014 plasticizer Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 abstract description 11
- 238000011282 treatment Methods 0.000 abstract description 8
- 239000000463 material Substances 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 42
- 239000003826 tablet Substances 0.000 description 20
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 14
- 241000282414 Homo sapiens Species 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 5
- 230000009102 absorption Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000006184 cosolvent Substances 0.000 description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
- 230000036765 blood level Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229940068917 polyethylene glycols Drugs 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 206010070863 Toxicity to various agents Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- VJZLQIPZNBPASX-OJJGEMKLSA-L prednisolone sodium phosphate Chemical compound [Na+].[Na+].O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 VJZLQIPZNBPASX-OJJGEMKLSA-L 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010003662 Atrial flutter Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010015856 Extrasystoles Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- XXMIOPMDWAUFGU-UHFFFAOYSA-N hexane-1,6-diol Chemical compound OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 description 1
- 229940063699 lanoxin Drugs 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229940113115 polyethylene glycol 200 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44496174A | 1974-02-22 | 1974-02-22 | |
| US444961 | 1974-02-22 | ||
| US45300074A | 1974-03-19 | 1974-03-19 | |
| US453000 | 1974-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1096307A true CA1096307A (en) | 1981-02-24 |
Family
ID=27034126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA220,535A Expired CA1096307A (en) | 1974-02-22 | 1975-02-21 | Pharmaceutical preparations |
Country Status (14)
| Country | Link |
|---|---|
| JP (1) | JPS50126822A (en, 2012) |
| AU (2) | AU501549B2 (en, 2012) |
| CA (1) | CA1096307A (en, 2012) |
| DE (1) | DE2507635A1 (en, 2012) |
| ES (1) | ES434971A1 (en, 2012) |
| FI (1) | FI750489A7 (en, 2012) |
| FR (1) | FR2261752B1 (en, 2012) |
| GB (1) | GB1506016A (en, 2012) |
| IE (1) | IE41620B1 (en, 2012) |
| IL (1) | IL46682A (en, 2012) |
| IT (1) | IT1233251B (en, 2012) |
| LU (1) | LU71894A1 (en, 2012) |
| NL (1) | NL7502121A (en, 2012) |
| SE (1) | SE426549B (en, 2012) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1508770A (en) * | 1974-04-01 | 1978-04-26 | Scherer Ltd R | Pharmaceutical compositions |
| US4002718A (en) * | 1974-10-16 | 1977-01-11 | Arnar-Stone Laboratories, Inc. | Gelatin-encapsulated digoxin solutions and method of preparing the same |
| DE2805165A1 (de) * | 1977-02-09 | 1978-08-10 | Christiaens Sa A | Gitoxin enthaltendes arzneimittel und verfahren zu seiner herstellung |
| IT1158722B (it) * | 1977-07-08 | 1987-02-25 | Simes | Composizione farmaceutica per il trattamento delle turbe del sonno |
| JPS5625428U (en, 2012) * | 1979-08-03 | 1981-03-09 | ||
| US4366145A (en) * | 1981-06-24 | 1982-12-28 | Sandoz, Inc. | Soft gelatin capsule with a liquid ergot alkaloid center fill solution and method of preparation |
| US4994260A (en) * | 1982-05-28 | 1991-02-19 | Astra Lakemedel Aktiebolag | Pharmaceutical mixture |
| SE8203953D0 (sv) * | 1982-06-24 | 1982-06-24 | Astra Laekemedel Ab | Pharmaceutical mixture |
| DE3445237C1 (de) * | 1984-12-12 | 1986-06-05 | R.P. Scherer GmbH, 6930 Eberbach | Weichgelatinekapseln und Verfahren zu ihrer Herstellung |
| DE3529694A1 (de) * | 1985-08-20 | 1987-02-26 | Scherer Gmbh R P | Gelatinekapseln und verfahren zu ihrer herstellung |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1481411A (en) * | 1973-07-20 | 1977-07-27 | Scherer Ltd R | Pharmaceutical compositions |
-
1975
- 1975-02-21 FI FI750489A patent/FI750489A7/fi not_active Application Discontinuation
- 1975-02-21 ES ES434971A patent/ES434971A1/es not_active Expired
- 1975-02-21 CA CA220,535A patent/CA1096307A/en not_active Expired
- 1975-02-21 NL NL7502121A patent/NL7502121A/xx active Search and Examination
- 1975-02-21 DE DE19752507635 patent/DE2507635A1/de active Granted
- 1975-02-21 JP JP50021803A patent/JPS50126822A/ja active Pending
- 1975-02-21 IL IL46682A patent/IL46682A/xx unknown
- 1975-02-21 LU LU71894A patent/LU71894A1/xx unknown
- 1975-02-21 IE IE371/75A patent/IE41620B1/en unknown
- 1975-02-21 GB GB7327/75A patent/GB1506016A/en not_active Expired
- 1975-02-21 AU AU78440/75A patent/AU501549B2/en not_active Expired
- 1975-02-21 FR FR7505457A patent/FR2261752B1/fr not_active Expired
- 1975-02-21 SE SE7501967A patent/SE426549B/xx not_active IP Right Cessation
-
1979
- 1979-05-28 AU AU47500/79A patent/AU520082B2/en not_active Ceased
-
1983
- 1983-11-28 IT IT8349395A patent/IT1233251B/it active
Also Published As
| Publication number | Publication date |
|---|---|
| IL46682A (en) | 1979-07-25 |
| GB1506016A (en) | 1978-04-05 |
| FR2261752B1 (en, 2012) | 1978-07-21 |
| IE41620B1 (en) | 1980-02-13 |
| SE7501967L (en, 2012) | 1975-08-25 |
| IT1233251B (it) | 1992-03-24 |
| AU520082B2 (en) | 1982-01-14 |
| JPS50126822A (en, 2012) | 1975-10-06 |
| ES434971A1 (es) | 1977-05-16 |
| IT8349395A0 (it) | 1983-11-28 |
| DE2507635A1 (de) | 1975-08-28 |
| AU501549B2 (en) | 1979-06-21 |
| IE41620L (en) | 1975-08-22 |
| DE2507635C2 (en, 2012) | 1991-07-25 |
| AU7844075A (en) | 1976-08-26 |
| SE426549B (sv) | 1983-01-31 |
| LU71894A1 (en, 2012) | 1975-12-09 |
| FR2261752A1 (en, 2012) | 1975-09-19 |
| FI750489A7 (en, 2012) | 1975-08-23 |
| IL46682A0 (en) | 1975-04-25 |
| NL7502121A (nl) | 1975-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4088750A (en) | Method and preparation for increasing bioavailability of digoxin | |
| EP2289496B1 (en) | Non-gelatin soft capsule system | |
| DK170110B1 (da) | Farmaceutisk præparat med langsom frigivelse og anvendelse af fumarsyre til fremstilling af præpar atet | |
| US7770361B2 (en) | Powder compaction and enrobing | |
| CA1096307A (en) | Pharmaceutical preparations | |
| RU2201754C2 (ru) | Фармацевтический состав, способ его получения, способ лечения психотических состояний и гиперактивности | |
| EP0804172B1 (en) | Controlled release potassium dosage form | |
| NO172027B (no) | Fremgangsmaate for fremstilling av et oralt farmasoeytisk preparat i fast enhets-doseform | |
| CA2341024A1 (en) | Non-gelatin substitutes for oral delivery capsules, their composition and process of manufacture | |
| JP2013509403A (ja) | 速溶性固体剤形 | |
| ZA975827B (en) | Stable medicament with benzimidazole derivatives as an active ingredient for oral administration and method for its production. | |
| CN103099799B (zh) | 复合膜状制剂及其制备方法 | |
| WO2009069139A1 (en) | Dosage form providing an ibuprofen-containing liquid fill | |
| DE58903856D1 (de) | Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung. | |
| EP0616802A1 (en) | Oral preparation for release in lower digestive tracts | |
| JPS61183220A (ja) | 鎮痛性を有する医薬組成物 | |
| CA1063024A (en) | Preparations containing n-(2-furfuryl)-4-chloro-5-sulfamoylanthranilic acid and process for their manufacture | |
| CN107441068B (zh) | 一种盐酸可乐定口腔膜剂及其制备方法 | |
| JPS6136491B2 (en, 2012) | ||
| Begum et al. | A review on manufacturing and evaluation of capsules | |
| AU2013200682B1 (en) | Fast Dissolving Solid Dosage Form | |
| EP0358710A1 (en) | Improved dry sustained release theophylline oral formulation | |
| JPH10502937A (ja) | フシジン酸錠剤の製法 | |
| RU2715680C2 (ru) | Таблетки ибупрофена натрия и способы изготовления фармацевтических композиций, включающих ибупрофен натрия | |
| EP0761209A2 (en) | Controlled release formulations of ranitidine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |